Singapore biotech startup Lucence expands across Asia, US as demand grows for preventive health tests
It aims to make its tests for the detection of cancer and other diseases more accessible
Add BT as a preferred source
[SINGAPORE] Singapore biotech startup Lucence is expanding across Asia and the US as it rides a growing wave of demand for preventive healthcare. At the forefront of its offerings are its liquid biopsy tests that can screen for up to 50 types of cancer, combining both DNA and RNA testing.
Lucence has obtained regulatory approval for these tests in the US; and Medicare, a government-funded health insurance programme in America, approved them for its beneficiaries in 2023.
Now the Mayo Clinic, one of the largest US healthcare groups, has partnered with it to distribute the tests across the country, said Dr Tan Min-Han, Lucence’s founder and CEO.
TRENDING NOW
China narrows AI gap with US as open-source shift could hit valuations: George Yeo
‘So little’?: Why critics of Temasek’s 10.5% returns in a bull run are getting it wrong
Samsung, SK Hynix and leveraged ETFs drive 70% of Korea trading, drawing criticism
Targeted credit relief: Vietnam steers funding to Vingroup, Sun Group, Masterise megaprojects
